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Abstract: Panel-based next generation sequencing (NGS) is currently preferred over whole exome
sequencing (WES) for diagnosis of familial breast cancer, due to interpretation challenges caused by
variants of uncertain clinical significance (VUS). There is also no consensus on the selection criteria
for WES. In this study, a pathology-supported genetic testing (PSGT) approach was used to select two
BRCA1/2 mutation-negative breast cancer patients from the same family for WES. Homozygosity for
the MTHFR 677 C>T mutation detected during this PSGT pre-screen step was considered insufficient
to cause bilateral breast cancer in the index case and her daughter diagnosed with early-onset breast
cancer (<30 years). Extended genetic testing using WES identified the RAD50 R385C missense
mutation in both cases. This rare variant with a minor allele frequency (MAF) of <0.001 was classified
as a VUS after exclusion in an affected cousin and extended genotyping in 164 unrelated breast cancer
patients and 160 controls. Detection of functional polymorphisms (MAF > 5%) in the folate pathway
in all three affected family members is consistent with inheritance of the luminal-type breast cancer in
the family. PSGT assisted with the decision to pursue extended genetic testing and facilitated clinical
interpretation of WES aimed at reduction of recurrence risk.
Keywords: breast cancer; exome sequencing; methylation pathway; pathology; pharmacogenomics
1. Introduction
Oncogenomics is a rapidly evolving integrative discipline that enables a novel approach to
the molecular characterization of breast cancer pathology. Understanding the relationship between
germline and tumour genetics is important in patients where early-onset familial breast cancer or
differences in drug response and survival outcome cannot be explained by mutations in the major
tumour suppressor genes, BRCA1 and BRCA2 [1–3]. In these circumstances, genome-scale microarray
analysis and/or next generation sequencing (NGS) provide viable options for comprehensive testing
in a well-defined target population. Application of these advanced molecular technologies in the
diverse South African population evolved into a pathology-supported genetic testing (PSGT) service
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used to facilitate the move from single- to multi-gene testing and NGS [4]. Utilization of PSGT may
extrapolate the capacity of NGS from genotype to phenotype.
NGS includes targeted sequencing of preselected gene panels as well as whole genome/exome
sequencing, RNA sequencing, and bisulfite sequencing for assessment of DNA methylation
patterns [5,6]. Although targeted sequencing panels are currently the method of choice in breast
cancer diagnostics, we favour the use of whole exome sequencing (WES) preceded by PSGT to facilitate
patient selection and clinical interpretation [7]. WES is not limited by the number of genes that can
be evaluated for risk of familial breast cancer and tailored therapeutic intervention in a single test.
However, the large amount of information that is generated throughout the coding region of the
genome may outpace our ability to adequately interpret variant pathogenicity for clinical application.
Comprehensive studies on the pathology of hereditary breast cancer is needed to characterize variants
of uncertain clinical significance (VUS) increasingly uncovered by WES [8,9], which may use lower
thresholds for breast cancer mutation screening compared to targeted BRCA1/2 mutation screening.
There is currently no consensus on eligibility criteria for WES in BRCA1/2 mutation-negative familial
breast cancer patients.
Grant et al. [10] demonstrated the value of a pre-screen algorithm using PSGT to reduce
chemotherapy overtreatment in South African breast cancer patients eligible for microarray analysis
using the 70-gene MammaPrint test. A similar approach was validated in the Microarray in
Node-negative Disease may Avoid ChemoTherapy (MINDACT) trial, which provided level 1A
evidence for the clinical utility of MammaPrint. Early-stage breast cancer patients classified as
clinical high-risk based on tumour size, grade, nodal status, estrogen receptor (ER) and human
epidermal growth factor receptor 2 (HER2) status, are eligible for microarray analysis [11]. The fact that
approximately 50% of early-stage breast cancer patients at high risk of recurrence could safely forego
chemotherapy based on a low-risk MammaPrint profile, confirmed the important role of genomics
to stratify breast cancer patients into different treatment groups. The finding that susceptibility
to a particular molecular subtype of breast cancer is associated with familial aggregation [8,12]
furthermore emphasised the importance of MammaPrint used in conjunction with the 80-gene
Blueprint microarray to subdivide tumours into the Luminal A, Luminal B, HER2-enriched and
basal-types [13,14].
Germline genotyping interpreted in the context of tumour subtype may help to determine whether
breast cancer is caused by genetic or environmental factors, or a combination of both, in order to direct
treatment accordingly. Naushad et al. [15] found that the Luminal A subtype is associated with lack of
family history of breast cancer, late age of onset and high body mass index (BMI), in contrast to the
basal-type known to be strongly associated with high-penetrance BRCA1 familial breast cancer [8].
In line with tumour pathology, genes involved in breast cancer can broadly be categorized into
those with high, moderate, and low penetrance of clinical manifestation. High-penetrance alleles
typically confer lifetime risks of breast cancer above 50%, while moderate penetrance alleles confer
risks greater than 20% and low-penetrance alleles increases of 10%–20% lifetime risk [16]. Risk above
50% is sufficient to recommend prophylactic surgery or magnetic resonance imaging screening in
a familial context. Risk reduction strategies based on low-moderate penetrance genes are focused
more on individual breast cancer survivors, where identification of biomarkers representing critical
biological processes may be targeted at the gene–environment level to reduce the incidence of breast
cancer recurrence.
It is estimated that known breast cancer susceptibility loci including BRCA1 and BRCA2 account
for approximately 20% of familial risk, with the remaining variation caused by mutations with
low-moderate penetrance that may be inherited in a subtype specific manner [17,18]. Failure to show
significant survival differences between patients with familial and sporadic breast cancer [19] may
partly be explained by polymorphic variation in drug metabolizing enzymes such as cytochrome
P450 (CYP) [20], or modifier genes dependent on nutrient co-factors. Folate and other B-vitamins are
important determinants of genome stability, yet might also contribute to the mechanism of action of
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anti-folates and fluoropyrimidines used in cancer treatment [21,22]. Xu et al. [22] identified one-carbon
metabolism as a key pathway to be targeted for improved breast cancer survival.
Germline variation in folate pathway genes is associated with aberrant patterns of tumour
pathology in cancer patients [23], with dysfunction of one-carbon metabolism found to be one of
the three most important disease mechanisms in the pathogenesis of cancer [24]. Growing evidence
of the complex interaction between methyl-related nutrients, alcohol and genetic variation in the
methylene tetrahydrofolate reductase (MTHFR) gene support individualised dietary recommendations
to reduce cancer risk in the general population [22,25]. These include substitution of low folate
foods with folate-dense fruits and vegetables in countries where there is no mandatory folic acid
fortification. Folate provides protection against carcinogenesis, especially in MTHFR mutation-positive
cases, yet high doses of the synthetic form (folic acid) are suspected to promote tumour growth when
administered after diagnosis of cancer. It is therefore reassuring that recent evidence obtained in
postmenopausal patients with increased folate intake through diet and/or supplementation showed
significantly higher circulating folate concentrations associated with improved survival after breast
cancer diagnosis [26]. Since the negative effects of low intakes of the methyl-related nutrients with
high intakes of alcohol are additive, Bailey [25] suggested that alcohol intake should be restricted to
less than 15 g per day, if consumed.
The low-penetrance MTHFR 677 C>T mutation found to be associated with hormone receptor
positive breast cancer [15], has previously been linked with increased BMI in South African patients
diagnosed with major depressive disorder [27]. A low folate score, as reflected by the nutrition
questionnaire used by Delport et al. [27], correlated with increased BMI and risk of depression in
South African patients with the MTHFR 677 C>T mutation. Depression is a major comorbidity
in breast cancer survivors and impacts on both the quality of life and treatment decision making.
In this context, Van der Merwe et al. [28] recommended CYP2D6 genotyping in breast cancer
patients who (1) receive tamoxifen treatment; and (2) are at increased recurrence risk due to a family
history of breast cancer/BRCA-mutation positivity; or (3) are required to take potential competing
antidepressants that may inhibit CYP2D6 enzyme function. CYP2D6 genotyping combined with the
unique spectrum of BRCA1/2 founder mutations identified in the South African population [29,30],
forms part of the pathology-supported pharmacogenetics test developed by van der Merwe [31] for
improved clinical management of patients with breast cancer and associated comorbidities. Combining
clinico-pathological features with pharmacogenetics in this chronic disease screening test is supported
by the findings of Phipps et al. [32,33], who demonstrated subtype association with a family history of
cancer and high BMI.
In this study, two BRCA1/2 mutation-negative breast cancer patients were selected from the same
family for WES, followed by extended mutation screening in 164 unrelated cases stratified according
to ER status. Lifestyle risk factors such as BMI were assessed in study participants due to the link
with cardiovascular disease (CVD), predicted to equal or exceed recurrence risk of breast cancer in
ER-positive postmenopausal women [34]. This approach can be extended into a PSGT pre-screen
algorithm for WES, to help distinguish between familial breast cancer eligible for NGS and patients
with lifestyle-related breast cancer who may reduce their recurrence risk by maintaining a healthy body
weight, smoking cessation and alcohol restriction [35]. These lifestyle factors may act in combination
with low-penetrance mutations underlying the folate-vitamin B12-methylation pathway evaluated
as part of a CVD multi-gene assay applied in this study before commencing WES [4]. Testing for
MTHFR 677 C>T as an invariant marker of increased risk for many chronic diseases associated with
dysfunctional methylation may add value beyond biochemical analysis of homocysteine and folate
levels, which are influenced by various environmental factors. For this reason, MTHFR is not only
a feasible anticancer drug target, but may also be considered an important factor in prevention of
cumulative disease risk across clinical entities.
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2. Results
2.1. Pathology-Supported Genetic Testing (PSGT)
Figure 1 illustrates the PSGT approach used to select the index case for WES. Despite bilateral
and early-onset breast cancer in the family, this patient tested negative for high-penetrance mutations
in the BRCA1 and BRCA2 genes. She was initially referred for the MammaPrint test and could safely
forego chemotherapy based on a low genomic risk for breast cancer recurrence. Microarray analysis
was preceded by immunohistochemistry (IHC) testing indicating ER-positive (ER+), progesterone
receptor-positive (PR+) and HER2-negative (HER2−) status. The index case remained disease-free
since 2008 despite termination of tamoxifen after one year due to severe side effects, including. Use of
the CVD multi-gene test excluded the most prevalent CYP2D6 null-allele in Caucasians (CYP2D6*4),
while homozygosity of MTHFR 677 C>T was detected in both the index case and her daughter with the
luminal-type breast cancer. It was uncertain whether this functional single nucleotide polymorphism
(SNP) expressed in a high-risk environment, as reflected by high BMI (>27 kg/m2) and inadequate
folate intake (score <14) in both cases, was sufficient for development of breast cancer in this family.
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low-risk recurrence score obtained with this microarray test, tamoxifen treatment was administered 
without addition of chemotherapy. Termination of tamoxifen after one year due to adverse drug 
response led to pharmacogenetic CYP2D6 genotyping, which was performed as part of a chronic 
disease screen incorporating the cardiovascular disease (CVD) multi-gene assay. Detection of the 
methylenetetrahydrofolate reductase (MTHFR) 677 C>T mutation identified dysfunction of the folate 
pathway as a potential target for recurrence risk reduction in this overweight patient. Evaluation of 
family history, clinical characteristics, and laboratory test results at the protein (IHC), RNA 
(MammaPrint) and DNA (BRCA1/2, CVD multi-gene assay) levels supported the decision to perform 
extended genetic testing using WES. BMI: body mass index; CYP: cytochrome P450. 
2.2. Comprehensive Cancer Panel Screen Using Whole Exome Sequencing 
WES was used to search for potentially causative gene variants in 409 known cancer-related 
genes included in the Ion AmpliSeq™ Comprehensive Cancer Panel (ThermoFisher, Waltham, MA, 
USA). Rare variants in the double strand break repair protein (RAD50 R385C, Refseq mRNA 
Figure 1. Outline of the pathology-supported genetic testing (PSGT) strategy used to select the
index case with bilateral BRCA1/2 mutation-negative breast cancer for whole exome sequencing
(WES). Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor
receptor-2 (HER2) status was determined using immunohistochemistry (IHC). These features, including
tumour size, grade and nodal status were evaluated to determine eligibility for MammaPrint.
Based on the low-risk recurrence score obtained with this microarray test, tamoxifen treatment was
administered without addition of chemotherapy. Termination of tamoxifen after one year due to
adverse drug respo se led to pharmacogenetic CYP2D6 genotyping, which was performed as part of
a chronic disease screen incorporating the cardiovascular disease (CVD) multi-gene assay. De ction
of the meth lenetetrahydrofolate red ctas (MTHFR) 677 C>T mutation identified dysfu ction of
the folate pathway as a potential target for recurrence risk reduction in this overweight patient.
Evaluation of family history, clinical characteristics, and laboratory test results at the protein (IHC),
RNA (MammaPrint) and DNA (BRCA1/2, CVD multi-gene assay) levels supported the decision to
perform extended genetic testing using WES. BMI: body mass index; CYP: cytochrome P450.
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2.2. Comprehensive Cancer Panel Screen Using Whole Exome Sequencing
WES was used to search for potentially causative gene variants in 409 known cancer-related
genes included in the Ion AmpliSeq™ Comprehensive Cancer Panel (ThermoFisher, Waltham, MA,
USA). Rare variants in the double strand break repair protein (RAD50 R385C, Refseq mRNA accession
NM_005732.3) and mucin 1 (MUC1 Q85E, Refseq mRNA accession NM_002456.5) genes were identified
as potential causative mutations. These missense mutations were confirmed using Sanger sequencing
(Figures 2 and 3).
Int. J. Mol. Sci. 2017, 18, 467  5 of 17 
 
accession NM_005732.3) and mucin 1 (MUC1 Q85E, Refseq mRNA accession NM_002456.5) genes 
were identified as potential causative mutations. These missense mutations were confirmed using 
Sanger sequencing (Figures 2 and 3). 
(A) (B) 
Figure 2. Detection of the RAD50 missense mutation R385C (rs139372231, Refseq mRNA accession 
NM_005732.3) using whole exome sequencing (A); and visualized using the Integrative Genome 
Viewer software tool [36]. The C to T base change at nucleotide position 1153 was confirmed by Sanger 
sequencing (B) as indicated by the arrow. 
(A) (B) 
Figure 3. Detection of the MUC1 missense mutation Q85E (rs773704188, Refseq mRNA accession 
NM_002456.5) using WES (A); and visualized using the Integrative Genome Viewer software tool 
[36]. The C to G base change at nucleotide position 325 was confirmed by Sanger sequencing (B) as 
indicated by the arrow. 
  
Figure 2. Detection of the RAD50 missense mutation R385C (rs139372231, Refseq mRNA accession
NM_005732.3) using whole exome sequencing (A); and visualized using the Integrative Genome
Viewer software tool [36]. The C to T base change at nucleotide position 1153 was confirmed by Sanger
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The RAD50 R385C mutation was detected in both the index case and her affected daughter,
while the MUC1 Q85E mutation was only identified in the daughter. Both mutations were absent in
a cousin of the index case diagnosed with breast cancer at the age of 42 years. Unlike RAD50, MUC1
has not been classified as a driver gene in breast cancer and was therefore not included in further
analysis. Bioinformatic analysis of RAD50 R385C with a minor allele frequency (MAF) of <0.001 is
shown in Table 1. Three of the seven software tools predicted a disease-causing damaging effect and
one a moderate impact.
Table 1. Bioinformatics analysis of missense mutation RAD50 R385C as a variant of uncertain
clinical significance.
Bioinformatics Tool Applied Predicted Biological Effect
Sorting Intolerant From Tolerant (SIFT) Damaging (rank score = 0.7209)
Polyphen Benign (score = 0.339)
Variant Effect Predictor Moderate impact
MutationTaster Disease causing (rank score = 0.8103)
MetalR Tolerated (rank score = 0.2311)
Provean Neutral (rank score = 0.4681)
Likelihood Ratio Test Deleterious (rank score = 0.5373)
2.3. Extended Mutation Analysis
Extended mutation screening for RAD50 R385C using allele-specific real-time polymerase chain
reaction (PCR) methodology excluded this rare variant in an additional 163 unrelated breast cancer
patients stratified according to ER status (49 ER-negative, 114 ER-positive). This missense mutation
was however detected in one (aged 36 years without a family history of cancer) of the 160 control
individuals screened, but absent in the cousin of the index case diagnosed with lobular invasive
carcinoma at the age of 42 years.
Failure to identify high impact pathogenic mutations in all affected family members prompted
extended analysis for functional polymorphisms (minor allele frequency > 1%) in the folate pathway
genes, methionine synthase (MTR) and methionine synthase reductase (MTRR). These genes are
included in the Ion AmpliSeq™ Comprehensive Cancer Panel used to identify the RAD50 and MUC1
rare variants. Two functional SNPs were detected in the MTR (2756 A>G, rs1805087) and MTRR
(66 A>G, rs1801394) genes, in addition to the low-penetrance MTHFR 677 C>T (rs1801133) mutation
previously identified using the testing algorithm illustrated in Figure 1. MTHFR 1298 A>C (rs1801131)
known to be in linkage disequilibrium with MTHFR 677 C>T was not detected. Extended analysis of the
CYP2D6 gene in the index case due to premature termination of tamoxifen, confirmed a fully functional
enzyme based on the gene region covered by WES. Figure 4 illustrates the clinical, histopathological
and genetic heterogeneity in the index patient, her daughter and cousin.
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3. Discussion
After excluding high-penetrance mutations in the coding regions of the BRCA1 and BRCA2 genes,
as well as screening for relatively common low-penetrance SNPs in key disease pathways underlying
genomic instability (MTHFR 677 C>T and 1298 A>C) and drug metabolism (CYP2D6*4), WES was
performed in the index patient and her daughter. An important aim was to determine whether
homozygosity for the MTHFR 677 C>T mutation may be sufficient to cause ER-positive breast cancer
in a high-risk nvironment as reflected by high BMI in both patients. WES identified a rar missense
mutation R385C in the DNA mismatch repair gene RAD50, in both t e mother and daughter. This rare
variant was excluded in a cousin diagnosed with invasive lobular carcinoma at the age of 42 years, as
well as a further 163 unrelated breast cancer patients selected from the genomics database. The index
case was diagnosed with bilateral breast cancer, invasive ductal and lobular carcinoma, while the
daughter was diagnosed with invasive ductal carcinoma. It is therefore possible that RAD50 R385C
may only be associated with invasive ductal carcinoma. However, detection of RAD50 R385C in one
of 160 controls screened and conflicting results obtained with use of several bioinformatics tools to
predict fun tionality, lassifies this missen mutation as a VUS.
Aloraifi et al. [37] identified RAD50 mutations in approxi ately 3% of genetically uncharacterised
breast cancer in a cohort of non-BRCA cases analysed. These authors reported potentially pathogenic
variants that may explain 35% of the missing heritability. Bodmer and Tomlinson [38] suggested that
whether or not rare variants end up filling the heritability gap, it is imperative to search for rare variants
alongside common variants. RAD50 has been documented as an intermediate-risk gene, attributable
to its critical role in the repair of DNA double strand breaks [39]. The RAD50 variant (rs139372231) is
a C to T base change at nucleotide position 1153 that results in an amino acid change from arginine to
cysteine at codon 385. The RAD50 protein forms a complex with the meiotic recombination 11 (MRE11)
and nibrin (NBN) double-strand break repair proteins, which bind to strands of damaged DNA and
hold broken ends together during the repair process. This MRE11-RAD50-NBN complex is important
to prevent accumulation of DNA damage that may trigger uncontrolled cellular division, in order to
promote maintenance of genome stability [40]. Pathogenic mutations in the RAD50 gene may lead
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to the production of an abnormally small, nonfunctional or missing RAD50 protein that may fail to
respond effectively to DNA damage [41].
This study has demonstrated the feasibility of WES to achieve a high level of comprehensive
genomic testing. The rare missense mutation Q85E, identified in the MUC1 gene in the daughter
of the index case with early-onset breast cancer, was absent in the mother and her affected cousin.
MUC1 is a transmembrane heterodimeric oncoprotein that is highly expressed in various cancers and
correlates with potential for malignancy [42]. Yamada et al. [41] reported that MUC1 gene expression
is regulated by DNA methylation and histone modification of the MUC1 promoter. They postulated
that an understanding of the epigenetic changes of MUC1 may be of importance for prediction of risk
and outcome for patients diagnosed with breast cancer. Deleterious germline mutations in the MUC1
gene is a well-documented cause of medullary cystic kidney disease, also known as mucin-1 kidney
disease [43]. In breast cancer, however, mutations in the MUC1 gene may only present as somatic
changes within tumour DNA, and are unlikely to be clinically useful in prediction of familial risk.
Thus, detection of this germline MUC1 mutation in the daughter may be considered an incidental
finding in relation to kidney disease, if proven to be pathogenic in future studies.
A shift in our focus to low-penetrance gene variants highlighted the potential significance of folate
pathway SNPs as a risk determinant for hormone receptor-positive breast cancer. Previous studies
have demonstrated that the genotype distribution and allele frequencies of SNPs in the MTHFR gene
differ significantly between population groups in South Africa [44]. The relatively high frequency
of MTHFR 677 C>T is not only of concern for cancer risk, but also in development of other chronic
diseases such as CVD. The SNP modifies the effect of hormone replacement therapy (HRT) on lipid
and metabolic parameters in postmenopausal women [45]. Homozygosity (TT genotype) for MTHFR
677 C>T is associated with a statistically significant increase in both total and low-density lipoprotein
(LDL) cholesterol levels, while presence of the C-allele is associated with a reduction in these lipid
levels after one year of HRT. The favourable effect of HRT on lipid levels was reversed in MTHFR
TT homozygotes.
The correlation of a given genomic risk profile with clinical and therapeutic outcomes as well as
risk for drug toxicity is complicated by clinico-pathological heterogeneity as observed in the family
studied here. The low-penetrance MTHFR 677 C>T mutation has previously been linked to the
luminal subtype of breast cancer [15], in a similar way that BRCA1 mutations predominate in patients
with hormone receptor-negative breast cancer of the basal-type. MTHFR 677 C>T has also been
implicated as a causative genetic determinant in altered expression of microRNAs (miRNAs) [46].
These short ≈22 nucleotide RNA regulators are involved in a wide spectrum of cellular processes
involving epigenetic changes [47]. The overall importance of polymorphic variation remains high due
to multiplicative effects, such that individuals possessing several functional polymorphisms may have
a significantly increased risk of breast cancer [48–50]. The presence of RAD50 R385C, in combination
with MTHFR 677 C>T previously identified as a BRCA-modifier gene [51], is consistent with the
modest family history reported by the index case.
Although functional SNPs do not confer significant individual risks for breast cancer, cumulative
data supported by WES suggest that co-inheritance of multiple low-penetrance mutations underlying
cancer pathways and rare variants in driver genes may explain the majority of non-BRCA familial
disease [52,53]. Variation in folate-pathway genes such as MTHFR, MTR and MTRR may disrupt
homeostasis and confer significant risk of breast cancer, attributable to impaired DNA repair [54,55].
Sangrajrang et al. [56] highlighted the role of genetic variation in the MTR and MTRR genes in relation
to menopausal status of breast cancer patients. Co-inheritance of MTHFR 677C>T with high-penetrance
causative mutations in the BRCA1/2 genes may increase the risk of early-onset breast/ovarian cancer,
while mutation 1298 A>C in the same gene is associated with sporadic breast cancer [51]. Elucidation
of the role of MTHFR as a modifier gene in familial breast cancer is of particular relevance in South
Africa, given the high frequency of founder BRCA1/2 mutations in Afrikaner, Coloured and Xhosa
breast cancer patients [29,30].
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Current literature does not suggest a particular strategy with regards to surveillance and
prophylactic management in patients with low-moderate risk variants [16]. However, combining
pathway-based SNP genotyping with BRCA founder mutation screening where appropriate,
may provide a viable risk reduction strategy for non-communicable diseases characterized by shared
disease pathways [4,7]. Due to constantly evolving genetic knowledge, the ideal breast cancer
susceptibility test remains elusive as it requires continuous development and refinement as new
information on VUS classification and clinical relevance of functional polymorphisms become available
in the scientific literature. The identification of actionable functional polymorphisms in important
disease pathways covered to a certain extent in the CVD multi-gene assay, which was recently extended
to include CYP2D6 pharmacogenetics [28,31], caused a paradigm shift in our understanding of the
pieces of the susceptibility puzzle. Implications for genetic counseling remains uncertain and can
only be comprehended by incorporating fixed genetic and modifiable environmental risk factors into
an existing body of knowledge. The PSGT strategy, which incorporates lifestyle factors with pathology
and genetic test results, strives to facilitate patient selection and clinical interpretation [4]. Improved
understanding of the genetic overlap between risk factors for ER-positive breast cancer and other
chronic diseases of lifestyle warrants consideration of a polygenic approach to disease prevention.
Limitations of the study include the fact that WES evaluates only the subset of DNA regions that
encode proteins (known as exons, or collectively the exome), which constitutes about 1% of the human
genome. There are approximately 20,000 genes encoded by an estimated 180,000 exons, but due to the
technological limitations of NGS previously reviewed [7], it is not feasible to completely cover every
single gene with 100% certainty. Clinically relevant mutations could therefore be missed in cases where
the gene region containing a disease-causing variant is not represented in the WES reads. Complex
genetic insertions or deletions are also not reliably detected by WES. We have previously illustrated
these problems in relation to the CYP2D6 gene, which could be addressed by using a combination of
different mutation detection methods to obtain reliable results [4]. A similar approach was followed
in this study. Furthermore, it has been shown that every healthy person carries several deleterious
mutations, without clinical manifestation of the associated medical condition due to gene–gene
and gene–environment interaction [57]. For this reason, information on VUS confirmed by Sanger
sequencing is stored in a database to gain knowledge from a larger number of samples in future.
The strength of this study lies in capturing genetic, pathology and lifestyle information before
and after WES to formulate pathway-based algorithms for breast cancer treatment and prevention.
The important role of gene–gene and gene–environment interaction has been emphasised previously
to explain the missing heritability in breast cancer. However, to our knowledge, this is the first study
to demonstrate the importance of functional SNPs in the MTHFR gene that could be further explored
by WES to confirm or support clinical relevance.
4. Materials and Methods
4.1. Ethics Approval
In response to a needs assessment survey amongst healthcare professionals in South Africa,
the PSGT platform was established to combine service delivery with health outcome studies [58].
Approval for this study and use of the genomics database was obtained from the Human Research
Ethics Committee of Stellenbosch University (reference number N09/08/224).
4.2. Study Population
Three members of the pedigree of the index case were included in this study. The index patient
diagnosed with breast cancer at the age of 57 years was referred for the MammaPrint test performed in
2008. She forms part of the cases included in the study of Grant et al. [10], who made special mention
of this patient due to a low-risk MammaPrint result for both tumours (invasive ductal and lobular
carcinoma). Her daughter was diagnosed with invasive ductal carcinoma approximately one year
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later, at the age of 29 years. A cousin was diagnosed with invasive lobular carcinoma at the age of
42 years. The index case experienced severe drug side-effects with use of tamoxifen, including vaginal
atrophy and hemorrhagic cystitis. She also reported folate supplementation to alleviate side-effects
during methotrexate treatment for arthritis.
A total of 164 unrelated female breast cancer patients (Table 2) and 160 controls without a family
history of breast cancer were included for extended mutation screening of variants detected by WES.
Except for a high BMI, the index case did not report any of the lifestyle risk factors listed in Table 2.
Periodic high alcohol consumption was reported in the affected daughter with early-onset breast
cancer treated with both tamoxifen and chemotherapy.
Table 2. Characteristics of 164 female breast cancer patients subdivided according to tumour pathology
into estrogen receptor (ER) positive (n = 49) and negative (n = 115) cases.
Variables ER-Negative ER-Positive
Median (Range) Number 49 115 *
Age (median, range) 164 49 (30–77) 54 (31–83)
Body mass index 146 25 (17–47) 26 (17–41)
Count (Percentage)
Ethnicity † 164 22 (45) 38 (33)
Family history of cancer 163 30 (61) 59 (52)
Hormone replacement therapy 163 9 (19) 15 (13)
Oral contraceptives 163 20 (42) 32 (28)
Current smoking 160 17 (35) 34 (30)
High alcohol consumption 156 25 (52) 62 (57)
* Includes the index case; † Percentage of non-Caucasian patients are indicated in brackets.
Patients with benign neoplasms of the breast or other malignancies were excluded from the study.
Only unrelated breast cancer patients with known ER status who signed informed consent for genetic
studies were selected for high-throughput genotyping, comprising 60 (37%) Coloured patients of mixed
ancestry and 104 (63%) Caucasians, including the index case. Patients with histopathology confirmed
breast cancer were recruited at the Tygerberg Hospital Breast Cancer Clinic or referred from private
practicing clinicians, as previously described by van der Merwe et al. [28]. Patients referred by clinicians
in private practice participated in a chronic disease screen using the CVD multi-gene assay [59] as
the core genetic component, recently extended to include CYP2D6 pharmacogenetics [31]. An online
questionnaire was used to obtain information on personal and family medical conditions, pathology,
medication use/side effects and lifestyle factors to enable clinical interpretation of the genetic findings.
Both the index patient and her affected 29-year old daughter tested positive for MTHFR 677 C>T,
investigated in this study as a potential contributing factor for breast cancer development against
a possible genetic background of rare variants that may be uncovered by WES. In this family with
inherited breast cancer, both the daughter (BMI 27.5 kg/m2) and her mother (BMI 27.8 kg/m2)
were overweight with suboptimal intake of folate-rich food in the diet (folate score < 14) according
to the nutrition and lifestyle assessment performed as previously described by Delport et al. [27].
The presence of BRCA1 and BRCA2 mutations was largely excluded as the cause of familial breast
cancer using NGS and multiplex ligation-dependent probe amplification (MLPA) at a commercial
laboratory (NewGene, Newcastle, UK).
4.3. DNA Extraction
DNA was extracted from whole blood using the spin protocol of QIAGEN QIAamp® DNA
Blood Mini Kit (Hilden, Germany) or Oragene reagents (Ottawa, ON, Canada) for saliva specimens,
according to the instructions provided with these commercially available kits. The NanoDrop®
ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, NC, USA) and its v3.5.2 software
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package was used to measure the DNA quality and quantity. All genomic DNA samples were diluted
to a final concentration of 10 ng/µL using nuclease-free water.
4.4. Whole Exome Sequencing
WES was performed at the Central Analytical Facility (Stellenbosch University, Stellenbosch,
South Africa) using the Ion Proton™ System (Thermo Fisher Scientific, Waltham, MA, USA) for
NGS. The Ion AmpliSeq™ Exome RDY Library Preparation protocol was used (Publication Number
MAN0010084) and template amplification was performed using the Ion PI™ Template OT2 200 Kit v3
(Thermo Fisher Scientific, Waltham, MA, USA) (Publication Number MAN0009133). Semi-conductor
sequencing on the Ion Proton system was performed using the Ion PI™ Sequencing 200 Kit v3
(Publication Number MAN0009136) with the Ion PI™ Chip Kit v2. This method is designed to target
all human exons. The sequencing run time on the Ion Proton™ System was approximately 4 h which
enabled the entire workflow from library construction to primary data analysis and result generation to
be done in under 24 h. The Torrent Suite™ (Thermo Fisher Scientific, Waltham, MA, USA) proprietary
software is the standard program through which this NGS apparatus operates and offered simple run
setup using predesigned workflows and run monitoring in real-time. WES analysis comprised several
intermediate steps involved in the read-processing pipeline, as illustrated in Figure 5.
First, sequence reads were aligned to the human reference genome (hg19) using the torrent
mapping alignment (TMAP) program [60]. This was followed by read analysis and processing using
the preinstalled Torrent Suite™ Software and variant calling with the Torrent Variant Caller (TVC)
plug-in. Mapped reads were processed in binary alignment/map (BAM) and indexed sequence
alignment/map (SAM) file format. TVC was used for functional annotation and filtering of variant
output in variant call files (VCFs). The finding that hg19 contains minor alleles at >1.5 million
loci led to repeat mapping of the reads to a synthetic Caucasian major allele reference sequence
(CEU-MARS) [61], following the same process illustrated in Figure 5. Resulting VCFs were then
processed using GeneTalk [62], a web-based tool for filtering and annotation of uploadable VCFs.
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Figure 5. A simplified representation of the data analysis pipeline used by Torrent Suite for the
identification of variants in WES data. Base calling, read filtering and trimming were performed by
the Torren Suite software. T e torrent mapping alignme t (TMAP) [60] program was used to map
the resulting reads to the human reference genome. Variant calling was performed by the Torrent
Variant Caller (TVC) in three steps: generate candidates, evaluate candidates and filter candidates.
Final filtering and annotation of variant call files (VCF) were performed using GeneTalk [62] web-based
bioinformatics tool.
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A coverage depth of 15× was used for detection of potentially causative gene variants, prior to
confirmation by Sanger sequencing. Coverage provides counts of read depth (DP) at two different
levels; the sample level where the DP value is the count of reads that passed the caller’s internal quality
control metrics and at the site level where this value is the unfiltered depth over all samples. In addition
to the aforementioned quality filters applied, rare variants were filtered on a population frequency
of <0.01% with variant function set to exclude all synonymous variants. A list containing 409 genes
from the Ion AmpliSeq™ Comprehensive Cancer Panel (Thermo Fisher Scientific, Waltham, MA,
USA; catalog number 4477685) was used to search for high impact mutations as well as polymorphic
variation in folate-related genes included in the panel. Bioinformatics tools freely available on the
internet (Table 1) were used to predict the functional effects for variants of interest.
4.5. Sanger Sequencing and Real-Time Polymerase Chain Reaction (PCR)
Following the identification of potentially causative variants or functional SNPs involved in
the folate pathway with use of WES, confirmation was performed by Sanger sequencing. Selected
variants were screened for in controls (n = 160) and the total breast cancer sample (n = 164) using
real-time PCR. Two microliters of template DNA (10 ng/µL) was used in a total reaction volume
of 10 µL. Applied Biosystems® (ABI™) (Foster City, CA, USA) TaqMan® SNP Genotyping Assays
were used for the real-time PCR runs according to standard TaqMan® SNP Genotyping protocols.
Pre-designed 40× assay mix consisted of unlabelled primers and TaqMan® Minor Groove Binder
(MGB) probes (VIC® and FAM™ dye-labelled). These assays were used for end-point genotyping by
allelic discrimination analysis for SNPs on the Corbett Rotor-Gene™ 6000 (Mortlake, New South Wales,
Australia) or Roche LightCycler® 480 II (Basel, Switzerland). The oligonucleotide primer sequences
used for Sanger sequencing and the TaqMan assays employed in this study are presented in Table 3.
Table 3. Oligonucleotide primers used for conventional polymerase chain reaction (PCR) and
Sanger sequencing, and the identification numbers of commercially available TaqMan assays used for
real-time PCR.
Gene dbSNP ID# Primer Oligonucleotide Primers forSanger Sequencing Size (bp)
TaqMan Assay
ID Numbers
MTHFR rs1801133
Forward ATCCCTCGCCTTGAACA
256 C_1202889_20Reverse TCACCTGGATGGGAAAGAT
MTR rs1805087
Forward GAACATCCCAAGCCCAC
595 C_12005959_10Reverse CACCTGTTTCCCTGCTG
MTRR rs1801394
Forward GTTTCATTCGTACACTCTCC
616 C_3068176_10Reverse CAGCATATGCTACTTCTGTC
RAD50 rs139372231
Forward ATCCACATGCTCAGGGGTAC
528 C_171053490_10Reverse GCCAAAATGGAGTCCAACC
MUC1 rs773704188
Forward ATTCCCAGCCACCACTCTGA
493 Not availableReverse CCCAACCTTAAGTGCACCAGT
bp: base pair, dnSNP: database of single nucleotide polymorphisms.
5. Conclusions
This study describes a framework for WES performed alongside clinical and pathology
assessments to provide a clear strategy for the way forward. We moved from single-gene analysis of
BRCA1/2 founder mutations in the high-risk South African population to multi-gene panel testing,
meant to assist clinicians in the decision to pursue WES. The selection of the index patient was primarily
based on the need to establish the role of MTHFR 677 C>T in familial risk, due to the potential for cancer
prevention at the population level. Our results support previous findings indicating that the majority
of genetically uncharacterised breast cancer cases may be caused by a combination of low–moderate
penetrance mutations exerting their effect against a high-risk clinical background. To our knowledge,
this is the first study using WES to investigate the significance of folate pathway SNPs as risk reduction
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targets beyond BRCA1/2 in familial risk. WES preceded by PSGT facilitated the identification and
clinical interpretation of genetic risk factors of relevance to both cancer development and tailored
therapeutic intervention in a single test.
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